| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
The primary targets of SB-267268 are the integrins αvβ3 and αvβ5, which are cell surface receptors that mediate cell adhesion to the extracellular matrix and play a key role in angiogenesis. SB-267268 acts as a selective and nonpeptidic antagonist of these integrins. It inhibits human and mouse αvβ3 with IC50s of 0.68 and 0.29 nM, respectively, and has Kis of 0.9 nM for human αvβ3, 0.5 nM for monkey αvβ3, and 0.7 nM for human αvβ5. The compound shows much less potent inhibition of αvβ6 integrin.
|
|---|---|
| ln Vitro |
SB-267268 exhibits a significantly reduced inhibitory impact on αvβ6 integrin in humans, mice, and rats. With an IC50 value of 12 nM, SB-267268 prevents αvβ3-transfected HEK293 cells from adhering to microtiter plate wells coated with arginine-glycine-aspartate (RGD)-containing matrix protein. Additionally, SB-267268 blocks the migration of rat and human aortic smooth muscle cells (SMC) mediated by vitronectin, with IC50 values of roughly 3.6 nM and 12.3 nM, respectively [1].
SB-267268 demonstrates potent in vitro inhibition of integrin-mediated cell adhesion and migration. It inhibits the attachment of αvβ3-transfected HEK293 cells to RGD-containing matrix proteins with an IC50 of 12 nM. The compound also inhibits vitronectin-mediated human and rat aortic smooth muscle cell migration with IC50 values of approximately 12.3 nM and 3.6 nM, respectively. SB-267268 reduces angiogenesis and VEGF expression in vitro. |
| ln Vivo |
SB-267268 (60 mg/kg; intraperitoneally injected twice daily) lowers intraretinal vascular profile (BVP) by 50% [1]. In ROP mice treated with SB-267268, VEGF and VEGFR-2 gene expression were reduced in the inner nuclear layer (INL) and ganglion cell layer (GCL) [1].
SB-267268 reduces pathologic angiogenesis in a mouse model of retinopathy of prematurity (ROP). At a dose of 60 mg/kg administered intraperitoneally twice daily, SB-267268 reduces blood vessel profiles in the inner retina by approximately 50%. In ROP mice treated with SB-267268, VEGF and VEGFR-2 gene expression in the inner retina is reduced. Importantly, the compound has no effect on developmental retinal angiogenesis in sham animals. |
| Enzyme Assay |
In vitro receptor binding assays for SB-267268 typically involve measuring its inhibition of integrin-mediated cell adhesion. αvβ3-transfected HEK293 cells are plated on microtiter plates precoated with RGD-containing matrix proteins in the presence of varying concentrations of SB-267268. The attachment of cells is measured, and the IC50 for inhibition is calculated, with SB-267268 showing an IC50 of 12 nM.
|
| Cell Assay |
Cellular assays for SB-267268 are performed in smooth muscle cells to assess its effects on cell migration. Human or rat aortic smooth muscle cells are plated in a migration chamber, and vitronectin is used as a chemoattractant in the presence of varying concentrations of SB-267268. The migration of cells is measured, and the IC50 for inhibition is calculated.
|
| Animal Protocol |
Animal/Disease Models: Pregnant female C57BL/6 mice (ROP mice) [1]
Doses: 60 mg/kg Route of Administration: intraperitoneal (ip) injection; twice (two times) daily Experimental Results: Inner retinal blood vessel profile (BVP) diminished by 50%. In vivo animal studies with SB-267268 have been performed in a mouse model of retinopathy of prematurity (ROP). In this model, mice are exposed to hyperoxic conditions to induce retinal neovascularization, and then returned to normoxia. SB-267268 is administered intraperitoneally at a dose of 60 mg/kg twice daily, and retinal angiogenesis is assessed by measuring blood vessel profiles and VEGF/VEGFR-2 gene expression. |
| ADME/Pharmacokinetics |
SB-267268 has a molecular weight of 451.44 and a molecular formula of C22H24F3N3O4. It is soluble in DMSO. The compound is stable when stored at -20°C in a dry, dark environment. However, detailed pharmacokinetic parameters such as absorption, distribution, metabolism, excretion, half-life, and bioavailability are not extensively reported in the available literature.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicology data for SB-267268 are not extensively reported. The compound is classified as a research-use-only chemical and is not intended for human consumption. In animal studies, SB-267268 had no effect on developmental retinal angiogenesis, suggesting a degree of selectivity for pathologic angiogenesis. Specific toxicological data, including acute toxicity, genotoxicity, and target organ effects, are not reported in the available literature.
|
| References | |
| Additional Infomation |
SB-267268 is a research-grade compound not approved for clinical use. Its primary application is as a pharmacological tool for studying the role of integrins αvβ3 and αvβ5 in angiogenesis. The compound is used to investigate the mechanisms of angiogenesis and to validate integrins as therapeutic targets for the treatment of diseases involving pathologic angiogenesis, such as cancer and retinopathy of prematurity.
|
| Molecular Formula |
C22H24F3N3O4
|
|---|---|
| Molecular Weight |
451.438876152039
|
| Exact Mass |
451.171
|
| CAS # |
205678-26-8
|
| Related CAS # |
205678-26-8
|
| PubChem CID |
9955461
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.1
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
32
|
| Complexity |
634
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
FC(CN1C([C@H](CC(=O)O)CC2C=CC(=CC=2C1)OCCCNC1C=CC=CN=1)=O)(F)F
|
| InChi Key |
PVDGZHKJXXVONO-INIZCTEOSA-N
|
| InChi Code |
InChI=1S/C22H24F3N3O4/c23-22(24,25)14-28-13-17-11-18(32-9-3-8-27-19-4-1-2-7-26-19)6-5-15(17)10-16(21(28)31)12-20(29)30/h1-2,4-7,11,16H,3,8-10,12-14H2,(H,26,27)(H,29,30)/t16-/m0/s1
|
| Chemical Name |
2-[(4S)-3-oxo-8-[3-(pyridin-2-ylamino)propoxy]-2-(2,2,2-trifluoroethyl)-4,5-dihydro-1H-2-benzazepin-4-yl]acetic acid
|
| Synonyms |
SB-267268 SB 267268 SB267268.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2151 mL | 11.0757 mL | 22.1513 mL | |
| 5 mM | 0.4430 mL | 2.2151 mL | 4.4303 mL | |
| 10 mM | 0.2215 mL | 1.1076 mL | 2.2151 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA